Xyata Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 17 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 45.71%
- Profit Growth 110.82%
- Ebitda 126.57%
- Net Worth 21.54%
- Total Assets 0.43%
About Xyata Life Sciences
Xyata Life Sciences Private Limited (XLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 October 2007 and has a history of 17 years and four months. Its registered office is in Delhi, India.
The Corporate was formerly known as Trava Life Sciences Private Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Tarun Jain and Arvinder Singh serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24230DL2007PTC169023
- Company No.
169023
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Oct 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Xyata Life Sciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arvinder Singh  | Director | 05-Oct-2007 | Current |
| Tarun Jain | Director | 05-Oct-2007 | Current |
Financial Performance of Xyata Life Sciences.
Xyata Life Sciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 45.71% increase. The company also saw a substantial improvement in profitability, with a 110.82% increase in profit. The company's net worth Soared by an impressive increase of 21.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xyata Life Sciences?
In 2022, Xyata Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sneakace Global Private LimitedTarun Jain is a mutual person
- Skytag Bioteq Llp
Arvinder Singh is a mutual person
- Cryotag Energy Solutions Llp
Arvinder Singh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Xyata Life Sciences?
Xyata Life Sciences has a workforce of 15 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xyata Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xyata Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.